TCRX stock icon

TScan Therapeutics
TCRX

$7.35
1.87%

Market Cap: 389M

 

About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Employees: 154

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 8 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

144% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 9

46% more capital invested

Capital invested by funds: $186M [Q4 2023] → $272M (+$86.3M) [Q1 2024]

33% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 4 (+1) [Q1 2024]

22% more funds holding

Funds holding: 54 [Q4 2023] → 66 (+12) [Q1 2024]

1694.3% less ownership

Funds ownership: 1772.94% [Q4 2023] → 78.64% (-1694.3%) [Q1 2024]

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$9
22%
upside
Avg. target
$12
63%
upside
High target
$15
104%
upside

8 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andrew Fein
104%upside
$15
Buy
Reiterated
4 Jun 2024
BTIG
Justin Zelin
63%upside
$12
Buy
Initiated
16 May 2024
HC Wainwright & Co.
Andrew Fein
104%upside
$15
Buy
Reiterated
14 May 2024
Needham
Gil Blum
50%upside
$11
Buy
Reiterated
13 May 2024
Wedbush
David Nierengarten
36%upside
$10
Outperform
Reiterated
23 Apr 2024

Financial journalist opinion